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by age, i.e., children and adolescents (Group A: 5–19) and adults
(Group B: 20+) and compared against an age matched control
group (Group C) (n = 10,2 million). Hospital admissions, out-
patient clinic visits, total nursing days, average length of stay
(ALOS), total hospital and specialist costs were analysed. Data
for the Control group (C) were based on 2001. Data are pre-
sented as a three-year average or otherwise speciﬁed. RESULTS:
The average number of hospital admissions and total nursing
days were; 434(A), 455(B), and 3159(A), 3691(B) respectively.
ALOS (days) were 7.3(A) and 5.3(C). In total there were
8696(A), 2680(B) outpatient clinic visits. Age matched controls
for category (A) had 88,134 days. Males (MPH group) account
for 78% of the total hospital admissions and 86% of outpatient
clinic visits. Sixty percent of the outpatient visits in MPH cate-
gory (A) occurred in age group 10–14, but 26% in age-matched
controls. Total hospital costs were 2800 M€ (A), 2840 M€ (B)
and 47,640 M€ (C) respectively. Specialist costs involved were
0.743 M€ (A), 0.344 M€ (B) and 7750 M€ for 5–19 years (C).
For the MPH group 21% and 28% of these costs were attrib-
uted to patients aged 5–19 years. Nearly 80% of the specialist
and hospital costs were dedicated to males. Average per patient
hospital costs were 258€(A) and 176€(C). CONCLUSIONS: The
data presented here show that ADHD patients have a substan-
tial health care consumption and related health care costs.
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OBJECTIVES: To determine the cost utility of medical co-pre-
scription of heroin compared with methadone maintenance
treatment for chronic, treatment resistant heroin addicts.
METHODS: In a Dutch multicenter study, 430 patients were
randomly assigned to a 1-year maintenance treatment with
methadone (maximum 150mg per day) or with methadone in
combination with inhalable or injectable heroin (maximum 1000
mg per day). Psychosocial treatment was offered throughout.
The primary outcome measures were the one-year costs from a
societal perspective and the number of quality adjusted life years
(QALYs) based on responses to the EQ-5D at baseline and at
various times during the treatment period. The incremental costs
per QALY ratio was calculated along with its 95% bootstrapped
conﬁdence interval. RESULTS: Co-prescription of heroin gener-
ated 0.058 (95% CI: 0.017–0.100) more QALYs on average than
treatment with methadone alone. Mean cost differences between
coprescribed heroin treatment and standard methadone treat-
ment resulted from the maintenance programme itself (17,634€
vs. 1412€ euro), law enforcement (8756 v 12,885 euro), damage
to victims (9617€ vs. 34,991€), and travel (600€ vs. 146€). The
mean total net costs resulting from co-prescribed heroin treat-
ment amounted to minus 12,793 (95% CI: -1049 to -25,169)€.
The incremental cost per QALY was minus 220,569 (95% CI: -
12,252 to -873,193)€. The cost acceptability of co-prescription
of heroin was more than 98.5% for willingness to pay values up
to 50,000€ per additional QALY. The probability of heroin co-
prescription being cost-effective for patients who were illegally
inactive at baseline was below 42%. The results were robust for
the exclusion of the initial implementation costs of heroin treat-
ment. CONCLUSIONS: Co-prescription of heroin is cost-
effective compared with treatment with methadone alone, even
in disregard of the intangible costs of victims of crime.
PMH18
ASSESSING THE TOTAL COST OF CARE FOR CEREBRAL
PALSY PATIENTS WHO USE BOTULINUM TOXIN TYPE A:
AN APPROACH TO CONTROLLING BIAS IN CASE CONTROL
STUDIES
Dickson M1, Kozma C2, Barron RL3
1University of South Carolina, Columbia, SC, USA; 2Independent
Outcomes Consultant, West Columbia, SC, USA; 3Allergan
Pharmaceuticals, Irvine, CA, USA
OBJECTIVES: The total cost of care (TC) for children with cere-
bral palsy (CP) who use botulinum toxin type A (BTX-A) was
compared to the TC for CP children not using BTX-A.
METHODS: A nested case control design compared BTX-A users
and non-users in the South Carolina Medicaid program from
1995 through 2001. Patients with at least one CP diagnosis
between 1996 and 1999 who were age 18 or younger were
included. They were followed for one year prior to study enroll-
ment, and 24 months after enrollment. A 1 :6 match of BTX-A
users to CP patients (non-BTX-A users) was performed using
propensity scores from a logistic regression model predicting
BTX-A use with demographics, CP severity, analgesia use, inpa-
tient hospitizations, Chronic Disease Score, CP comorbidities,
and pre-period TC. Cases and controls were compared using
logistic regression on post-period data to estimate the same model
predicting BTX-A use. RESULTS: BTX-A users (n = 58) were
identiﬁed and matched to 348 randomly selected non-users. After
matching, the cases and controls were not statistically different
on any of the model variables used in the matching procedure.
Estimation of the ﬁnal model revealed that only CP severity was
signiﬁcantly related to BTX-A use (diplegia p = 0.0107, hemi-
plegia p < 0.0001, and quadraplegia p < 0.001). The Hazard Ratio
for these variables revealed the likelihood of BTX-A use relative
to the lowest CP severity level (diplegia HR = 5.91, hemiplegia
HR = 23.88, and quadraplegia HR = 10.22). While BTX-A is
most frequently used in more severe patients, a statistically sig-
niﬁcant difference in total cost of care was not found (p = 0.528).
CONCLUSIONS: While a greater percentage of CP children
treated with BTX-A had more severe diagnoses, their TC was not
different from CP children not using BTX-A after controlling for
prior-period conditions using propensity scores.
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OBJECTIVES: To evaluate the cost-effectiveness of the ﬁrst long-
acting atypical anti-psychotic injection (risperidone long-acting
injection), compared to a weighted comparator of oral risperi-
done, oral olanzapine and typical depot injections for the man-
agement of patients with schizophrenia, who are partially
adherent to their medication in the specialized public psychiatry
setting. The perspective of the analysis was the Australian health
care system. METHODS: A 1-year decision analytic model was
developed using probabilistic sensitivity analysis to explore
uncertainty. The outcomes used in the cost-effectiveness analysis
(CEA) were relapses avoided, deaths due to suicide averted and
